Patents Assigned to Elan Pharma International Limited
-
Publication number: 20080227719Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: August 20, 2007Publication date: September 18, 2008Applicant: Elan Pharma International LimitedInventors: Dale B. SCHENK, Nicki VASQUEZ, Theodore YEDNOCK
-
Publication number: 20080227718Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: August 20, 2007Publication date: September 18, 2008Applicant: Elan Pharma International LimitedInventors: Dale B. SCHENK, Nicki VASQUEZ, Theodore YEDNOCK
-
Patent number: 7384413Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to The device may also be provided with manually control for delivering a bolus dose of drug when necessary.Type: GrantFiled: June 13, 2003Date of Patent: June 10, 2008Assignee: Elan Pharma International LimitedInventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
-
Publication number: 20080124389Abstract: The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.Type: ApplicationFiled: April 12, 2006Publication date: May 29, 2008Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080113025Abstract: The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.Type: ApplicationFiled: June 25, 2007Publication date: May 15, 2008Applicant: Elan Pharma International LimitedInventors: John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080102121Abstract: The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.Type: ApplicationFiled: June 25, 2007Publication date: May 1, 2008Applicant: Elan Pharma International LimitedInventors: John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080096818Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: August 20, 2007Publication date: April 24, 2008Applicant: Elan Pharma International LimitedInventors: Dale Schenk, Nicki Vasquez, Theodore Yednock
-
Publication number: 20070298098Abstract: The invention relates to a controlled release composition comprising levetiracetam for the treatment of epilepsy. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of levetiracetam and the modified release component or formulation preferably comprises a second population of levetiracetam and a controlled release constituent. The modified release formulation is preferably in the form of an erodable formulation, a diffusion controlled formulation or an osmotic controlled formulation. The combination of the immediate release component and the modified release component or formulation in operation deliver the active ingredient in a pulsed or bimodal manner.Type: ApplicationFiled: February 14, 2006Publication date: December 27, 2007Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Scott Jenkins, Gary Liversidge
-
Publication number: 20070238154Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.Type: ApplicationFiled: February 16, 2007Publication date: October 11, 2007Applicants: Elan Pharma International Limited, WyethInventors: Guriq Basi, Jose Saldanha, Dale Schenk
-
Patent number: 7256273Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.Type: GrantFiled: March 12, 2003Date of Patent: August 14, 2007Assignees: Elan Pharma International Limited, WyethInventors: Guriq Basi, Jose Saldanha
-
Patent number: 7101576Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: April 14, 2003Date of Patent: September 5, 2006Assignee: Elan Pharma International LimitedInventors: Douglas Hovey, John Pruitt, Tuula Ryde
-
Patent number: 7021163Abstract: An apparatus and method for monitoring the dissolution properties of a solid dosage form pharmaceutical or other material. The apparatus includes a hollow dissolution chamber for supporting the dosage form and subjecting it to a dissolution liquid so that the dosage form dissolves in the liquid. A dissolution liquid analyzing device (e.g., a spectrophotometer) analyzes the properties of the dissolution liquid as the dosage form dissolves. A video monitoring means (e.g., a stereo-microscope and video camera) provides a series of images of the dosage form as it dissolves. The series of images and data resulting from the analysis are recorded and correlated. The temperature, flow rate and chemical parameters of the dissolution liquid can be controlled (e.g., held constant or altered), if desired.Type: GrantFiled: October 9, 2002Date of Patent: April 4, 2006Assignee: Elan Pharma International LimitedInventor: Oliver Kyne
-
Patent number: 6991191Abstract: A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor. A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate.Type: GrantFiled: April 28, 2004Date of Patent: January 31, 2006Assignee: Elan Pharma International, LimitedInventors: Robert Gary Reed, David A. Czekai, Henry William Bosch, Niels-Peter Moesgaard Ryde
-
Patent number: 6976647Abstract: A system for milling at least one material, e.g., a drug, is described. The system includes a milling apparatus. In another embodiment of the invention, the system includes at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.Type: GrantFiled: December 11, 2003Date of Patent: December 20, 2005Assignee: Elan Pharma International, LimitedInventors: Robert G. Reed, David Czekai
-
Patent number: 6974588Abstract: A transdermal patch for administering a volatile liquid drug, such as nicotine, transdermally to a patient comprising a four-layer laminated composite of: a top drug impermeable backing layer; a pressure sensitive silicone adhesive layer containing the drug; a pressure sensitive acrylic adhesive layer also containing the drug; and a removable siliconized release liner layer. Also disclosed is a method for treating a person for nicotine dependence and particularly for treating a woman for nicotine dependence.Type: GrantFiled: December 7, 1999Date of Patent: December 13, 2005Assignee: Elan Pharma International LimitedInventors: Jesus Miranda, Charles J. Betlach, II
-
Patent number: 6843782Abstract: A drug delivery device having a base member defining a skin-contacting surface, a syringe serving as a reservoir for the drug, and means for expelling drug from the syringe. The syringe is connected to the base member such that the longitudinal axis of the syringe is substantially parallel to the skin surface. A delivery needle is in communication with the syringe. The needle has an angled bend which directs the tip of the needle substantially perpendicular to the skin-contacting surface. In use, the tip of the needle is adapted to penetrate the skin of the subject.Type: GrantFiled: April 18, 2001Date of Patent: January 18, 2005Assignee: Elan Pharma International LimitedInventors: Joseph Gross, Gilad Lavi, Izrail Tsals
-
Patent number: 6824529Abstract: A drug delivery device having a base member defining a skin-contacting surface, a syringe serving as a reservoir for the drug, and means for expelling drug from the syringe. The syringe is connected to the base member such that the longitudinal axis of the syringe is substantially parallel to the skin surface. A delivery needle is in communication with the syringe. The needle has an angled bend which directs the tip of the needle substantially perpendicular to the skin-contacting surface. In use, the tip of the needle is adapted to penetrate the skin of the subject.Type: GrantFiled: April 17, 2001Date of Patent: November 30, 2004Assignee: Elan Pharma International LimitedInventors: Joseph Gross, Gilad Lavi, Izrail Tsals
-
Patent number: 6811767Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.Type: GrantFiled: June 19, 2000Date of Patent: November 2, 2004Assignee: Elan Pharma International LimitedInventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
-
Publication number: 20040164194Abstract: A system for milling at least one material, e.g., a drug, is described. The system includes a milling apparatus. In another embodiment of the invention, the system includes at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.Type: ApplicationFiled: December 11, 2003Publication date: August 26, 2004Applicant: Elan Pharma International LimitedInventors: Robert G. Reed, David Czekai
-
Patent number: 6745962Abstract: A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor. A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate.Type: GrantFiled: October 19, 2001Date of Patent: June 8, 2004Assignee: Elan Pharma International LimitedInventors: Robert Gary Reed, David A. Czekai, Henry William Bosch, Niels-Peter Moesgaard Ryde